Literature DB >> 3779104

In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes.

A Lichtenstein, T Ganz, M E Selsted, R I Lehrer.   

Abstract

We examined the activity of defensins, cysteine-rich cationic peptides that are abundant in the cytoplasmic granules of human and rabbit granulocytes, against various tumor targets. The three human defensins, HNP-1, HNP-2, and HNP-3, lysed human and murine targets in chromium release and dye exclusion assays. Defensin-mediated tumor cell lysis was concentration-dependent, inhibited by serum, and dependent on temperature-sensitive events. Lysis was first detected by three hours of incubation and it reached a plateau between eight and 14 hours. In vitro exposure of murine teratocarcinoma cells to HNP 1-3 abrogated their oncogenicity in vivo. Nonmalignant target cells were also susceptible to defensin-mediated lysis. Four rabbit granulocyte defensins exerted marked (NP-1, NP-2) or moderate (NP-3a, NP-3b) cytotoxic activity, whereas defensin NP-5 was not cytotoxic. When tumor cells were incubated with human defensins in combination with hydrogen peroxide, synergistic cytotoxicity was detected. As defensins are released from granulocytes by various stimuli, their release could contribute to extracellular cytotoxicity which is independent of reactive oxygen intermediates.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3779104

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  69 in total

1.  Defensins impair phagocytic killing by neutrophils in biomaterial-related infection.

Authors:  S S Kaplan; R P Heine; R L Simmons
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Dynamic changes in neutrophil defensins during endotoxemia.

Authors:  M E Klut; B A Whalen; J C Hogg
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

Review 3.  Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects.

Authors:  Amy A Baxter; Fung T Lay; Ivan K H Poon; Marc Kvansakul; Mark D Hulett
Journal:  Cell Mol Life Sci       Date:  2017-08-02       Impact factor: 9.261

Review 4.  Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells.

Authors:  T Ganz; A Oren; R I Lehrer
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 5.  The use of therapeutic peptides to target and to kill cancer cells.

Authors:  R J Boohaker; M W Lee; P Vishnubhotla; J M Perez; A R Khaled
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 6.  Epithelial antimicrobial defence of the skin and intestine.

Authors:  Richard L Gallo; Lora V Hooper
Journal:  Nat Rev Immunol       Date:  2012-06-25       Impact factor: 53.106

7.  Relationship between antibody-dependent tumour cell lysis and primary granule exocytosis by human neutrophils.

Authors:  F Dallegri; G Frumento; A Ballestrero; R Goretti; F Patrone
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

8.  Psoriasis-Associated Late Cornified Envelope (LCE) Proteins Have Antibacterial Activity.

Authors:  Hanna Niehues; Lam C Tsoi; Danique A van der Krieken; Patrick A M Jansen; Merel A W Oortveld; Diana Rodijk-Olthuis; Ivonne M J J van Vlijmen; Wiljan J A J Hendriks; Richard W Helder; Joke A Bouwstra; Ellen H van den Bogaard; Philip E Stuart; Rajan P Nair; James T Elder; Patrick L J M Zeeuwen; Joost Schalkwijk
Journal:  J Invest Dermatol       Date:  2017-06-17       Impact factor: 8.551

9.  Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes.

Authors:  B L Kagan; M E Selsted; T Ganz; R I Lehrer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

10.  Killing of Giardia lamblia by cryptdins and cationic neutrophil peptides.

Authors:  S B Aley; M Zimmerman; M Hetsko; M E Selsted; F D Gillin
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.